
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
Sandy Kweder, deputy director of the FDA's Office of New Drugs, talks about the implications of the FDA's announcement earlier this year that all prescription combinations of opioids and acetaminophen are required to contain no more than 325 mg of acetaminophen per tablet.






